

A pregnant woman with blonde hair is lying in a hospital bed, wearing a light blue hospital gown. She is looking off to the side with a calm expression. In the foreground, resting on her lap, is the Actim 1ngeni device, a small, grey, rectangular point-of-care instrument. The device has a digital screen displaying icons for 'HOME', 'READY TO USE', 'TEST', 'RESULTS', 'SETTINGS', and 'HELP'. A test strip is partially inserted into the front of the device. The background is a soft-focus hospital room with white curtains and a door.

# Actim<sup>®</sup> Partus 1ngeni

## The next-generation Actim<sup>®</sup> Partus 1ngeni

### **Quantitative confidence for prediction of preterm delivery**

Thanks to the quantitative test method, the next generation Actim<sup>®</sup> Partus 1ngeni not only detects or rules out the risk of preterm or imminent delivery, but also provides precise data about the severity of the risk, giving you the confidence in choosing early and crucial treatment strategies.

Actim Partus 1ngeni quantitatively measures phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) concentration in cervical secretions. The higher the concentration, the higher the risk.

Actim Partus 1ngeni test results are quantified and interpreted, displayed and stored automatically and consistently by using the Actim<sup>®</sup> 1ngeni instrument. This digital point-of-care system is logical and intuitive to use, and provides quantitative test results in just 5 minutes.

## Clinical performance

The clinical performance of the quantitative Actim Partus 1ngeni was validated in a retrospective study in 691 women with signs and symptoms of preterm delivery. Of these women, 360 experienced spontaneous delivery. Elevated pHIGFBP-1 concentration correlated with an increased risk of imminent or preterm delivery (Table 1).

**Table 1.**

Relative risk of preterm delivery categorized according to pHIGFBP-1 concentration in Actim Partus 1ngeni test.

pHIGFBP-1 concentration (ng/mL)	Delivery ≤ 7 days	Delivery ≤ 14 days	Delivery before 30 weeks	Delivery before 34 weeks	Delivery before 37 weeks
≤ 2	–	–	–	–	–
2.1–9.9	5.3*	1.5	0.5	1.4	1.6*
10.0–49.9	5.8*	2.1	5.8*	3.3**	2.4***
50.0–249.9	7.7*	4.2*	11.5**	4.1**	2.4***
≥ 250	13.5**	11.1***	20.3***	8.7***	3.9***

Relative risk compared to pHIGFBP-1 ≤ 2 ng/mL z-statistics significance:

\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

## The Actim Partus 1ngeni test is performed using the Actim 1ngeni instrument



### Fast and easy testing with traceable documentation

Automated testing and digital data storage save time and ensure assay consistency. The results are reported in just 5 minutes.

### Clear quantification and interpretation of test results

The pHIGFBP-1 concentration is reported as a numerical value with the description of estimated risk for preterm or imminent labor:

< 10 ng/mL, low risk of preterm delivery

≥ 10 ng/mL, elevated risk of preterm delivery

### Early prediction of preterm or imminent delivery

Actim Partus 1ngeni test is taken from cervical secretions in women with intact fetal membranes and can be performed from gestational week 22 onwards. Accurate detection of an elevated risk is crucial for choosing the right treatment early.

### Actim Oy

– a subsidiary of Medix Biochemica

Klovinpellontie 3, FI-02180 Espoo, Finland

actim@actimtest.com

[www.actimtest.com](http://www.actimtest.com)

Product availability and/or labeling may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.  
© 09/2020 Actim Oy. All rights reserved. Actim is a registered trademark of Actim Oy.